• 1. An insight into the origin of room-temperature ferromagnetism in SnO2 and Mn-doped SnO2 quantum dots: an experimental and DFT approach?
  Dhamodaran Manikandan,S. Amirthapandian,I. S. Zhidkov,A. I. Kukharenko,S. O. Cholakh,Ramaswamy Murugan Phys. Chem. Chem. Phys., 2018,20, 6500-6514
• 2. An amide probe as a selective Al3+ and Fe3+ sensor inside the HeLa and a549 cell lines: Pictet–Spengler reaction for the rapid detection of tryptophan amino acid?
  Bidyut Kumar Kundu,Rinky Singh,Ritudhwaj Tiwari,Debasis Nayak New J. Chem., 2019,43, 4867-4877
• 3. An integrated droplet-digital microfluidic system for on-demand droplet creation, mixing, incubation, and sorting?
  Lab Chip, 2019,19, 524-535
• 4. An atomically efficient, highly stable and redox active Ce0.5Tb0.5Ox (3% mol.)/MgO catalyst for total oxidation of methane?
  Juan J. Sánchez,Miguel López-Haro,Juan C. Hernández-Garrido,Ginesa Blanco,Miguel A. Cauqui,José M. Rodríguez-Izquierdo,José A. Pérez-Omil,José J. Calvino,María P. Yeste J. Mater. Chem. A, 2019,7, 8993-9003
• 5. An alumina stabilized graphene oxide wrapped SnO2 hollow sphere LIB anode with improved lithium storage?
  Xiang Liu,Qian Sun,A. B. Djuri?i?,Maohai Xie,Baohu Dai,Jinyao Tang,Charles Surya,Changzhong Liao,Kaimin Shih RSC Adv., 2015,5, 100783-100789

Introduction to 4-bromo-3-(propan-2-yl)-1H-indazole (CAS No. 693285-71-1)

4-bromo-3-(propan-2-yl)-1H-indazole, identified by the Chemical Abstracts Service Number (CAS No.) 693285-71-1, is a heterocyclic organic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal research. This compound belongs to the indazole class, a structural motif widely recognized for its biological activity and utility in drug development. The presence of a bromine substituent at the 4-position and an isopropyl group at the 3-position introduces unique electronic and steric properties, making it a valuable scaffold for synthetic exploration and therapeutic applications.

The indazole core is a fused bicyclic system consisting of a benzene ring and a pyrrole ring, which is known to exhibit diverse pharmacological effects. The bromine atom, being an electronegative element, can participate in various chemical reactions such as cross-coupling reactions, which are fundamental in modern organic synthesis. Additionally, the isopropyl group introduces steric hindrance and potential for hydrogen bonding interactions, influencing the compound's solubility and binding affinity to biological targets.

In recent years, 4-bromo-3-(propan-2-yl)-1H-indazole has been extensively studied for its potential as an intermediate in the synthesis of bioactive molecules. Its structural features make it a versatile building block for creating more complex pharmacophores. Researchers have leveraged its reactivity to develop novel compounds with applications in oncology, inflammation, and central nervous system disorders. The bromine atom at the 4-position facilitates palladium-catalyzed cross-coupling reactions, enabling the introduction of aryl or vinyl groups to expand the molecular diversity.

One of the most compelling aspects of 4-bromo-3-(propan-2-yl)-1H-indazole is its role in the development of kinase inhibitors. Kinases are enzymes that play a crucial role in cell signaling pathways, and their dysregulation is often associated with diseases such as cancer. By modifying the indazole scaffold, chemists have been able to design inhibitors that selectively target specific kinases. For instance, derivatives of this compound have shown promise in inhibiting tyrosine kinases, which are overactive in many cancer types. The isopropyl group at the 3-position can be tailored to optimize binding interactions with the kinase active site, enhancing potency and selectivity.

The pharmaceutical industry has also explored 4-bromo-3-(propan-2-yl)-1H-indazole as a precursor for antiviral agents. Indazole derivatives have demonstrated antiviral activity against various pathogens by interfering with viral replication mechanisms. The bromine substituent allows for further functionalization through Suzuki-Miyaura cross-coupling reactions, enabling the introduction of fluoro or chloro groups that can improve pharmacokinetic properties. Additionally, the propan-2-yl side chain can be modified to enhance cell membrane permeability, a critical factor for drug efficacy.

Recent advances in computational chemistry have further accelerated the discovery process for 4-bromo-3-(propan-2-yl)-1H-indazole derivatives. Molecular modeling techniques allow researchers to predict binding affinities and optimize lead structures before experimental synthesis. This approach has been particularly useful in identifying compounds with high binding specificity to protein targets. By integrating experimental data with computational predictions, scientists can rapidly screen large libraries of indazole derivatives and identify promising candidates for further development.

The synthesis of 4-bromo-3-(propan-2-yl)-1H-indazole itself involves multi-step organic transformations that highlight its synthetic utility. Common synthetic routes include bromination of pre-existing indazole derivatives followed by nucleophilic substitution with isopropyl halides or Grignard reagents. These methods showcase the versatility of indazole chemistry and provide access to a wide range of structural variations. The ability to efficiently introduce different substituents at strategic positions on the indazole core allows for fine-tuning of biological activity.

In conclusion, 4-bromo-3-(propan-2-yl)-1H-indazole (CAS No. 693285-71-1) represents a significant advancement in pharmaceutical chemistry due to its unique structural features and synthetic flexibility. Its applications in kinase inhibition, antiviral therapy, and other therapeutic areas underscore its importance as a research tool and drug development intermediate. As new methodologies emerge in medicinal chemistry and computational biology, compounds like 4-bromo-3-(propan-2-yl)-1H-indazole will continue to play a pivotal role in discovering novel therapeutics that address unmet medical needs.

• 61485-22-1(1H-Indazole, 3-(1-methylpropyl)-)
• 199172-01-5(6-Bromo-3-ethyl-1H-indazole)
• 90221-46-8(6-Bromo-3-methyl-1H-indazole)
• 864774-67-4(5-Bromo-3-ethyl-1H-indazole)
• 7746-27-2(6-Bromo-3-methyl-1H-indazole)
• 1197943-62-6(5-Bromo-3-propyl-1H-indazole)
• 1314987-32-0(6-Bromo-3-butyl-1H-indazole)
• 1314988-13-0(5-Bromo-3-butyl-1H-indazole)
• 911305-80-1(5-Bromo-3-cyclopropyl-1H-indazole)
• 61485-19-6(3-(1-methylethyl)-1H-Indazole)